

# David R Martinez

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3803842/david-r-martinez-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47  
papers

7,079  
citations

26  
h-index

55  
g-index

55  
ext. papers

10,304  
ext. citations

27.1  
avg. IF

5.7  
L-index

#	Paper	IF	Citations
47	Targeted isolation of panels of diverse human protective broadly neutralizing antibodies against SARS-like viruses. <b>2022</b> ,		3
46	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease. <b>2022</b> ,		2
45	Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice.. <i>Science Translational Medicine</i> , <b>2022</b> , 14, eabm3410	17.5	7
44	Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses.. <i>Journal of Virology</i> , <b>2022</b> , e0023122	6.6	
43	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. <i>Science Translational Medicine</i> , <b>2021</b> , eabj7125	17.5	24
42	Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine. <i>Nature</i> , <b>2021</b> ,	50.4	9
41	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	171
40	Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques. <i>Journal of Virology</i> , <b>2021</b> ,	6.6	40
39	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice <b>2021</b> ,		11
38	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	169
37	A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice <b>2021</b> ,		24
36	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. <i>Nature</i> , <b>2021</b> , 594, 553-559	50.4	85
35	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100313	18	24
34	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , <b>2021</b> , 373,	33.3	80
33	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice <b>2021</b> ,		5
32	The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates <b>2021</b> ,		27
31	Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants <b>2021</b> ,		13

30	Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals <b>2021</b> ,		8
29	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. <i>Cell Reports</i> , <b>2021</b> , 36, 109450	10.6	23
28	Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. <i>MSphere</i> , <b>2021</b> , 6, e0027521	5	11
27	In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , <b>2021</b> , 184, 4203-4219.e32	56.2	89
26	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. <i>Science</i> , <b>2021</b> , 373, 991-998	33.3	48
25	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> , <b>2021</b> , 373, 1372-1377	33.3	150
24	Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice <b>2021</b> ,		9
23	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. <i>Journal of Virology</i> , <b>2021</b> , 95, e0097421	6.6	3
22	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , <b>2021</b> , 184, 5432-5447.e16	56.2	34
21	Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection. <i>Cell Host and Microbe</i> , <b>2021</b> , 29, 13-22	23.4	3
20	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , <b>2020</b> , 369, 812-817	33.3	592
19	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <i>Science</i> , <b>2020</b> , 369, 806-811	33.3	748
18	Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies. <i>Cell Host and Microbe</i> , <b>2020</b> , 27, 710-724.e7	23.4	7
17	SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. <i>Cell</i> , <b>2020</b> , 182, 429-446.e14	56.2	710
16	Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold. <i>MAbs</i> , <b>2020</b> , 12, 1778435	6.6	37
15	The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. <i>Science Immunology</i> , <b>2020</b> , 5,	28	450
14	Maternal gatekeepers: How maternal antibody Fc characteristics influence passive transfer and infant protection. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1008303	7.6	11
13	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. <i>Cell Reports</i> , <b>2020</b> , 32, 107940	10.6	260

12	Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. <i>Nature Medicine</i> , <b>2020</b> , 26, 1422-1427	50.5	283
11	SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness <b>2020</b> ,		62
10	Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions <b>2020</b> ,		7
9	Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees. <i>Cell Reports</i> , <b>2020</b> , 33, 108226	10.6	13
8	A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. <i>Nature</i> , <b>2020</b> , 586, 560-566	50.4	299
7	High Potency of a Bivalent Human V Domain in SARS-CoV-2 Animal Models. <i>Cell</i> , <b>2020</b> , 183, 429-441.e16	56.2	67
6	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , <b>2020</b> , 586, 567-571	50.4	594
5	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , <b>2020</b> , 586, 583-588	50.4	550
4	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1544-1555	59.2	612
3	Potently neutralizing and protective human antibodies against SARS-CoV-2. <i>Nature</i> , <b>2020</b> , 584, 443-449	50.4	609
2	Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 29832-29838	11.5	57
1	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. <i>DMM Disease Models and Mechanisms</i> , <b>2020</b> , 13,	4.1	26